Announcement on the Resignation of Core Technical Personnel
Filed with SSE · · 3 pages · Chinese
Bio-Thera Solutions, Ltd. on 6ix
Earlier from Bio-Thera Solutions
- Announcement on Completing Industrial and Commercial Change Registration of Registered Address and Amending the Articles of Association
- Announcement on Attending 2025 Online Collective Reception Day for Investors in Guangdong Jurisdiction
- Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) Injection
- Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of Qletli (Adalimumab Solution for Injection) by UK MHRA
- Announcement on Convening the Semi-annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2025
Later from Bio-Thera Solutions
- Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in Canada
- Announcement on Voluntary Disclosure of Progress in the Receipt of the Initial Payment from STADA for the Signing of the Licensing and Commercialization Agreement for BAT1806 (Tocilizumab) Injection
- Report for Q3 2025
- Announcement on Convening the Q3 2025 Performance Briefing
- Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions